Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hemorrhagic Fevers, Viral

ClinicalTrials.gov lists 483 trials for Hemorrhagic Fevers, Viral or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 63.

MeSH D006482 Infections C01 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 126 Phase 1/2 Phase 1/2 16 Phase 2 Phase 2 93 Phase 2/3 Phase 2/3 12 Phase 3 Phase 3 46 Phase 4 Phase 4 10 Not applicable Not applicable 58 Observational Observational 120 Phase 1 Phase 1 126 Phase 1/2 Phase 1/2 16 Phase 2 Phase 2 93 Phase 2/3 Phase 2/3 12 Phase 3 Phase 3 46 Phase 4 Phase 4 10 Not applicable Not applicable 58 Observational Observational 120

Trials per phase

1 more section with rows

38 of the 483 trials are tagged with Hemorrhagic Fevers, Viral itself; the rest are tagged with a narrower condition beneath it.

Get the Hemorrhagic Fevers, Viral report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hemorrhagic Fevers, Viral trials start? (25)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 5 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 37

2001: 1 trials (Phase 2 1) 2003: 2 trials (Phase 1/2 1, Phase 1 1) 2004: 4 trials (Phase 2 2, Phase 1/2 1, Phase 1 1) 2005: 2 trials (Phase 1/2 1, Phase 1 1) 2006: 11 trials (Observational 2, Not applicable 1, Phase 2 4, Phase 1 4) 2007: 8 trials (Observational 3, Phase 2 2, Phase 1 3) 2008: 10 trials (Phase 4 1, Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 3) 2009: 13 trials (Observational 1, Phase 3 1, Phase 2 7, Phase 1 4) 2010: 19 trials (Observational 4, Not applicable 2, Phase 3 2, Phase 2 2, Phase 1 9) 2011: 16 trials (Observational 3, Not applicable 1, Phase 3 6, Phase 2 1, Phase 1 5) 2012: 13 trials (Observational 3, Not applicable 1, Phase 2 2, Phase 1/2 1, Phase 1 6) 2013: 12 trials (Observational 3, Phase 2 3, Phase 1 6) 2014: 29 trials (Observational 4, Not applicable 2, Phase 2/3 2, Phase 2 7, Phase 1/2 1, Phase 1 13) 2015: 37 trials (Observational 6, Not applicable 1, Phase 4 1, Phase 3 3, Phase 2/3 2, Phase 2 4, Phase 1/2 3, Phase 1 17) 2016: 31 trials (Observational 9, Not applicable 6, Phase 3 6, Phase 2 5, Phase 1 5) 2017: 19 trials (Observational 8, Not applicable 1, Phase 4 2, Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 2) 2018: 27 trials (Observational 7, Not applicable 4, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 6) 2019: 21 trials (Observational 4, Not applicable 2, Phase 4 2, Phase 3 3, Phase 2 5, Phase 1 5) 2020: 20 trials (Observational 8, Not applicable 4, Phase 3 1, Phase 1/2 2, Phase 1 5) 2021: 34 trials (Observational 7, Not applicable 5, Phase 3 1, Phase 2/3 1, Phase 2 10, Phase 1/2 1, Phase 1 9) 2022: 27 trials (Observational 7, Not applicable 5, Phase 4 1, Phase 3 2, Phase 2 6, Phase 1 6) 2023: 23 trials (Observational 6, Not applicable 8, Phase 3 2, Phase 2 5, Phase 1/2 1, Phase 1 1) 2024: 31 trials (Observational 13, Not applicable 6, Phase 4 1, Phase 3 1, Phase 2 6, Phase 1/2 1, Phase 1 3) 2025: 37 trials (Observational 14, Not applicable 3, Phase 4 1, Phase 3 7, Phase 2/3 3, Phase 2 4, Phase 1 5)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 28
2025 37
2024 31
2023 23
2022 27
2021 34
2020 20
2019 21
2018 27
2017 19

Showing 10 of 25 earlier years.

Start your 14-day trial Email me all 25 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 36 trials starting in 2026 and about 35 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 27 months from start to primary completion across 37 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 336 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hemorrhagic Fevers, Viral trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 126
Phase 1/2 16
Phase 2 93
Phase 2/3 12
Phase 3 46
Phase 4 10
Not applicable 58
Observational 120
Expanded access 2

How many Hemorrhagic Fevers, Viral trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 18
Recruiting 42
Enrolling by invitation 3
Active, not recruiting 22
Available 2

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hemorrhagic Fevers, Viral trials? (9)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 63
Sanofi Pasteur, a Sanofi Company 35
U.S. Army Medical Research and Development Command 27
Takeda 17
Sanofi 9

Showing 5 of 9 sponsors.

Start your 14-day trial Email me all 9 sponsors as a PDF

Which drugs are being tested for Hemorrhagic Fevers, Viral? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Yellow Fever Vaccine 22
AVIGAN 5
Remdesivir 4

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
CYD Dengue Vaccine 11
Ribavirine 11
Ad26. ZEBOV 9
MVA-BN-Filo 8
TDV 6

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hemorrhagic Fevers, Viral trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Dengue Fever 600 5
Appendicitis 525 25
Road Traffic Accident 263 6
Gastroenteritis 252 19
Urinary Tract Infection 221 5

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hemorrhagic Fevers, Viral? (4)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Structural landscape of the complete genomes of dengue virus serotypes and other viral hemorrhagic fevers. BMC genomics 2021 Yes
Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Virology journal 2010 Yes
Emerging infectious diseases at the beginning of the 21st century. Online journal of issues in nursing 2006 No
Exotic emerging viral diseases: progress and challenges. Nature medicine 2004 No

Prevalence (3)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Viral hemorrhagic fever Point prevalence Unknown Worldwide Not stated Unspecified
Viral hemorrhagic fever Point prevalence Unknown Worldwide Not stated Exact
Viral hemorrhagic fever Point prevalence Unknown Worldwide Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Viral hemorrhagic fever 341 Exact Orphanet Rare Disease Ontology (ORDO)
Viral hemorrhagic fever 341 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (8)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages